{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:13Z","timestamp":1792785853367,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Midlands Gastroenterology Society and GUTS UK","id":[{"id":"https:\/\/ror.org\/002kcsx52","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced therapies, including biologics and small molecule drugs, are increasingly used in the management of inflammatory bowel disease (IBD), but their diverse characteristics can influence patient treatment choices and experiences. Understanding patient priorities and practicing shared decision-making can optimize treatment satisfaction and adherence. This qualitative study explored patient experiences on advanced therapies to identify factors influencing treatment decisions aiming to develop a practical tool supporting shared decision-making when initiating or switching treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Using purposive sampling, participants on advanced therapies for moderate-to-severe IBD were recruited through Crohn\u2019s &amp; Colitis UK and social media until achieving data saturation. Semi-structured interviews were conducted using a topic guide developed from literature review and patient representative input. Audio recordings were transcribed and analyzed using reflexive thematic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 26 participants, most were female (73.1%) and using Vedolizumab (30.7%) or Infliximab (26.9%). The age group 31-40 (34.6%) was most commonly represented, and 46.2% had ulcerative colitis. All participants were in self-reported clinical remission. Four overarching themes were identified: embedding treatment realities into daily routines; negotiating the tension between therapeutic benefits and potential risks; navigating formal and informal support structures; and asserting agency in treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patient decision-making around advanced therapies for the management of moderate-to-severe IBD is influenced by treatment practicality and life impact, balancing efficacy and risk management, access to healthcare support networks, and involvement in care decisions. The Advanced therapy options, choice, access, and treatment empowerment for IBD tool, developed from these findings, provides clinicians with a framework to understanding individual patient priorities and values, supporting meaningful shared decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag098","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:18:56Z","timestamp":1788520736000},"source":"Crossref","is-referenced-by-count":0,"title":["Advanced therapy options, choice, access, and treatment empowerment for inflammatory bowel disease (ADVOCATE-IBD): a UK-wide semi-structured interview study exploring patient preferences around advanced therapy decisions in inflammatory bowel disease"],"prefix":"10.1093","volume":"8","author":[{"given":"Ronit","family":"Hardasani","sequence":"first","affiliation":[{"name":"School of Medicine, University of Leicester , Leicester LE1 7RH,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-0810","authenticated-orcid":false,"given":"Shellie Jean","family":"Radford","sequence":"additional","affiliation":[{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham NG7 2UH,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3004-375X","authenticated-orcid":false,"given":"Mohammad Farhad","family":"Peerally","sequence":"additional","affiliation":[{"name":"SAPPHIRE, Division of Public Health and Epidemiology, University of Leicester , Leicester LE1 7RH,","place":["United Kingdom"]},{"name":"Digestive Disease Unit, Kettering General Hospital, University Hospitals of Northamptonshire NHS Group , Kettering NN16 8UZ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"2026091822215809900_otag098-B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S2468-1253(19)30358-9","article-title":"Global burden of inflammatory bowel disease","volume":"5","author":"Jairath","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026091822215809900_otag098-B2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5217\/ir.2015.13.1.4","article-title":"The positive influences of increasing age at diagnosis of inflammatory bowel disease on disease prognostication in Asian perspective","volume":"13","author":"Ali","year":"2015","journal-title":"Intest Res"},{"key":"2026091822215809900_otag098-B3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0016-5085(81)80021-2","article-title":"Incidence rates of ulcerative colitis and Crohn\u2019s disease in fifteen areas of the United States","volume":"81","author":"Garland","year":"1981","journal-title":"Gastroenterology"},{"key":"2026091822215809900_otag098-B4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10620-016-4363-3","article-title":"Perceived emotional and psychological impact of ulcerative colitis on outpatients in Spain: UC-LIFE survey","volume":"62","author":"L\u00f3pez-Sanrom\u00e1n","year":"2017","journal-title":"Dig Dis Sci"},{"key":"2026091822215809900_otag098-B5","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3390\/ph16091272","article-title":"Pharmacological therapy in inflammatory bowel diseases: a narrative review of the past 90 years","volume":"16","author":"Imbrizi","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026091822215809900_otag098-B6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jval.2015.12.001","article-title":"Patient-centered outcomes of medication adherence interventions: systematic review and meta-analysis","volume":"19","author":"Conn","year":"2016","journal-title":"Value Health"},{"key":"2026091822215809900_otag098-B7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"Am J Med"},{"key":"2026091822215809900_otag098-B8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ajg.2009.685","article-title":"Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review","volume":"105","author":"Jackson","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2026091822215809900_otag098-B9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.15171\/mejdd.2016.16","article-title":"Nonadherence to medication in inflammatory bowel disease: rate and reasons","volume":"8","author":"Ghadir","year":"2016","journal-title":"Middle East J Dig Dis"},{"key":"2026091822215809900_otag098-B10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.dld.2016.01.013","article-title":"Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: a real world-based study","volume":"48","author":"Peyrin-Biroulet","year":"2016","journal-title":"Dig Liver Dis"},{"key":"2026091822215809900_otag098-B11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2147\/CEG.S206970","article-title":"Patient and physician preferences for ulcerative colitis treatments in the United States","volume":"12","author":"Boeri","year":"2019","journal-title":"Clin Exp Gastroenterol"},{"key":"2026091822215809900_otag098-B12","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1007\/s12325-022-02143-z","article-title":"Inflammatory bowel disease patients\u2019 treatment preferences using a discrete choice experiment technique: the InPuT study","volume":"39","author":"Schubert","year":"2022","journal-title":"Adv Ther"},{"key":"2026091822215809900_otag098-B13","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/ibd.21888","article-title":"Systematic assessment of factors influencing preferences of Crohn\u2019s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL)","volume":"18","author":"Vavricka","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2026091822215809900_otag098-B14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/ecco-jcc\/jjac145","article-title":"What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study","volume":"17","author":"Schoefs","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026091822215809900_otag098-B15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1590\/S0004-2803.202000000-86","article-title":"Factors associated with patient\u2019s preference in choosing their therapy for inflammatory bowel disease in Brazil","volume":"57","author":"Wu","year":"2020","journal-title":"Arq Gastroenterol"},{"key":"2026091822215809900_otag098-B16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40271-017-0294-0","article-title":"Factors that influence treatment and non-treatment decision making among individuals with inflammatory bowel disease: an integrative review","volume":"11","author":"Kamp","year":"2018","journal-title":"Patient"},{"key":"2026091822215809900_otag098-B17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1159\/000528586","article-title":"Inflammatory bowel disease patients\u2019 preferences for subcutaneous versus intravenous therapies: a mixed-methods study","volume":"41","author":"Van Deen","year":"2023","journal-title":"Dig Dis"},{"key":"2026091822215809900_otag098-B18","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1093\/ibd\/izae015","article-title":"Patient preferences for treatment attributes in inflammatory bowel disease: results from a large survey across seven European countries using a discrete choice experiment","volume":"30","author":"Fiorino","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026091822215809900_otag098-B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/RHXR5192","article-title":"Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study","volume":"26","author":"Coates","year":"2022","journal-title":"Health Technol Assess"},{"key":"2026091822215809900_otag098-B20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14780887.2013.801543","article-title":"Sampling in interview-based qualitative research: a theoretical and practical guide","volume":"11","author":"Robinson","year":"2014","journal-title":"Qual Res Psychol"},{"key":"2026091822215809900_otag098-B21","doi-asserted-by":"publisher","first-page":"114523","DOI":"10.1016\/j.socscimed.2021.114523","article-title":"Sample sizes for saturation in qualitative research: a systematic review of empirical tests","volume":"292","author":"Hennink","year":"2022","journal-title":"Soc Sci Med"},{"key":"2026091822215809900_otag098-B22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/2159676X.2019.1628806","article-title":"Reflecting on reflexive thematic analysis","volume":"11","author":"Braun","year":"2019","journal-title":"Qual Res Sport Exerc Health"},{"key":"2026091822215809900_otag098-B23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MIB.0000000000001033","article-title":"Development of the IBD disk: a visual self-administered tool for assessing disability in inflammatory bowel diseases","volume":"23","author":"Ghosh","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026091822215809900_otag098-B24","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1111\/jocn.13740","article-title":"Health care as perceived by persons with inflammatory bowel disease - a focus group study","volume":"26","author":"Lesnovska","year":"2017","journal-title":"J Clin Nurs"},{"key":"2026091822215809900_otag098-B25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.18553\/jmcp.2014.20.3.309","article-title":"Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis","volume":"20","author":"Devlen","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"2026091822215809900_otag098-B26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000253862","article-title":"Patients\u2019 preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study","volume":"81","author":"Baars","year":"2010","journal-title":"Digestion"},{"key":"2026091822215809900_otag098-B27","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.crohns.2014.02.013","article-title":"Patients\u2019 perceptions, attitudes, and experiences about the management of mild-to-moderate ulcerative colitis","volume":"8","author":"Casellas","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2026091822215809900_otag098-B28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/ecco-jcc\/jjz131","article-title":"Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review","volume":"14","author":"Colombel","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026091822215809900_otag098-B29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"2026091822215809900_otag098-B30","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2026091822215809900_otag098-B31","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1053\/j.gastro.2020.05.063","article-title":"Innovation in inflammatory bowel disease care during the COVID-19 pandemic: results of a global telemedicine survey by the international organization for the study of inflammatory bowel disease","volume":"159","author":"Lees","year":"2020","journal-title":"Gastroenterology"},{"key":"2026091822215809900_otag098-B32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S2468-1253(19)30340-1","article-title":"Personalised medicine in Crohn\u2019s disease","volume":"5","author":"Noor","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026091822215809900_otag098-B33","doi-asserted-by":"publisher","first-page":"2042533313478004","DOI":"10.1177\/2042533313478004","article-title":"How do online patient support communities affect the experience of inflammatory bowel disease? an online survey","volume":"4","author":"Coulson","year":"2013","journal-title":"JRSM Short Rep"},{"key":"2026091822215809900_otag098-B34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/1049732316680203","article-title":"Online peer-to-peer communities in the daily lives of people with chronic illness: a qualitative systematic review","volume":"27","author":"Kingod","year":"2017","journal-title":"Qual Health Res"}],"container-title":["Crohn\u2019s &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag098\/70828321\/otag098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag098\/70828321\/otag098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:22:02Z","timestamp":1789784522000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otag098\/8772366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag098","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"otag098"}}